Next-Generation Complement Therapeutics Market Poised for Strong Growth as Targeted Treatments for Immune and Infectious Diseases Expand

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Next-Generation Complement Therapeutics Market Size, Share & Trends Analysis Report By Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, and Neuromyelitis Optica), Therapeutic Area (Cardiovascular, Genetic, Hematological And Vascular, Infectious, Neurological), Molecule Type, Type Of Therapy, Route Of Administration (Intravenous, Oral, And Subcutaneous), Region, Market Outlook And Industry Analysis 2034"

According to the latest research by InsightAce Analytic, the global next-generation complement therapeutics market is valued at USD 5,070.9 Mn in 2024 , and it is expected to reach USD 12,983.6 Mn, with a CAGR of 10.0% during the forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2269

The complement system plays a vital role in innate immunity and the maintenance of tissue homeostasis, providing protection against infections while facilitating the clearance of apoptotic cells and debris. However, it also contributes to the pathogenesis of various inflammatory and autoimmune diseases, prompting research institutions and industries to develop innovative next-generation therapeutic drugs targeting specific proteins and functions within the complement system.

Several factors are expected to drive the growth of the next-generation complement therapeutics market during the forecast period. These include the high prevalence of immune system and infectious diseases, ongoing clinical trials focused on complement-targeted therapeutics, and the increasing clinical research efforts to develop complement-based treatments. Additionally, the rapid adoption of next-generation technologies and the availability of well-established healthcare infrastructures are further fueling market expansion. The rising number of clinical studies on complement-targeted therapeutics for conditions such as COVID-19, cardiac transplant rejection, and paroxysmal nocturnal hemoglobinuria is also expected to provide substantial growth opportunities. However, the undiagnosed population with complement deficiencies may present a challenge to widespread market adoption in the coming years.

Regionally, North America is projected to maintain its leadership in the next-generation complement therapeutics market during the forecast period (2022-2031), driven by the rapid adoption of advanced technologies and substantial investments in research and development aimed at creating novel complement-targeted therapies. Europe is expected to hold the second-largest share of the market in terms of revenue.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Key market players operating in the next-generation complement therapeutics market include Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, and UCB, among others.

Key Developments In The Market:
• In Oct 2022, Amgen announced that the acquisition of ChemoCentryx, Inc. has been effectively finalized. The acquisition comprises TAVNEOS®, an orally administered selective complement 5a receptor inhibitor that received adjunctive therapy approval from the U.S. Food and Drug Administration (FDA) in October 2021. The standard of care for adults with severe active ANCA-associated vasculitis typically consists of cyclophosphamide or rituximab immunosuppressant therapy. TAVNEOS® is intended to supplement this regimen. The acquisition also includes an oral checkpoint for cancer and three early-stage drug candidates that target chemoattractant receptors and other inflammatory diseases, in addition to TAVNEOS®.
• In Feb 2022, EnjaymoTM (sutimlimab-jome) was granted approval by the U.S. Food and Drug Administration (FDA) for the purpose of reducing the necessity for red blood cell transfusions in adults diagnosed with cold agglutinin disease (CAD) caused by hemolysis. As the first and only approved treatment for CAD, Enjaymo functions by impeding the process of red blood cell degradation, also known as hemolysis.Enjaymo was granted approval in the United States on the basis of positive results from the CARDINAL study, a 26-week open label, single arm pivotal Phase 3 trial involving 24 patients with CAD and a recent history of blood transfusion.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2269

Market Segments
Global Next-Generation Complement Therapeutics Market, by Target Disease Indication, 2022-2031 (Value US$ Mn)
• Atypical Hemolytic Uremic Syndrome
• Paroxysmal Nocturnal Hemoglobinuria
• Cardiac Transplantation Rejection
• Cold Agglutinin Disease
• COVID-19
• Generalized Myasthenia Gravis
• Guillain-Barre Syndrome
• Hereditary Angioedema
• Neuromyelitis Optica
Global Next-Generation Complement Therapeutics Market, by Therapeutic Area, 2022-2031 (Value US$ Mn)
• Cardiovascular
• Genetic
• Hematological and Vascular
• Infectious
• Neurological and Neuromuscular Disorders
Global Next-Generation Complement Therapeutics Market, by Molecule Type, 2022-2031 (Value US$ Mn)
• Biologic
• Small Molecule
Global Next-Generation Complement Therapeutics Market, by Type of Therapy, 2022-2031 (Value US$ Mn)
• Monotherapy
• Combination Therapy
Global Next-Generation Complement Therapeutics Market, by Route of Administration, 2022-2031 (Value US$ Mn)
• Intravenous
• Oral
• Subcutaneous
Global Next-Generation Complement Therapeutics Market, by Region, 2022-2031 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Next-Generation Complement Therapeutics Market, by Country, 2022-2031 (Value US$ Mn)
• U.S.
• Canada
Europe Next-Generation Complement Therapeutics Market, by Country, 2022-2031 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Next-Generation Complement Therapeutics Market, by Country, 2022-2031 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Next-Generation Complement Therapeutics Market, by Country, 2022-2031 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Next-Generation Complement Therapeutics Market, by Country, 2022-2031 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Read Overview Report- https://www.insightaceanalytic.com/report/next-generation-complement-therapeutics-market/2269

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.